TY - JOUR
T1 - P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis
AU - Høgdall, Estrid V S
AU - Høgdall, Claus K
AU - Blaakaer, Jan
AU - Heegaard, Niels H H
AU - Glud, Eva
AU - Christensen, Lise
AU - Bock, Johannes E
AU - Nørgaard-Pedersen, Bent
AU - Wiik, Allan
AU - Kjaer, Susanne K
PY - 2002/8
Y1 - 2002/8
N2 - The p53 gene, a tumour suppressor gene located on the short arm of chromosome 17 (17p13), is frequently mutated in various human tumours. Accumulation of p53 protein in neoplastic cells and its release following tumour necrosis can lead to development of circulating autoantibodies (AAb) against p53. Earlier studies of ovarian cancer (OC) patients reported different frequencies of p53 AAb and conclusions regarding the clinical and prognostic value of these AAb have not been in agreement. We therefore analysed for the presence of p53 AAb in a total of 227 preoperative serum samples from 193 OC patients and 34 patients with ovarian borderline tumours, and, in addition, serum samples from 86 healthy controls. An enzyme-linked immunosorbent assay (ELISA) was used to measure serum IgG antibodies against p53. The p53 protein used in the assay was produced as a hexahistidine-tagged fusion protein by baculovirus-infected Spodoptera frugiperda cells. Cut-off values for p53 AAb were evaluated, and correlations of p53 AAb with clinical-, biochemical data and survival were examined. We found a low sensitivity for p53 AAb alone, and no major additional effect of the detection rate of CA125 was found. No significant associations were found between p53 AAb and clinical stage, age, histological subtype and radicality after primary surgery. In contrast, we found significantly elevated CA125 levels in p53 AAb-positive patients compared to lower CA125 levels in p53 AAb-negative patients (p=0.003). No significant differences were found between p53 AAb-positive and p53 AAb-negative patients in the univariate and multivariate survival analyses. In conclusion, in a screening study for OC serum p53 AAb levels are of no diagnostic value, even if combined with the tumour marker CA125. The presence of increased serum p53 AAb in patients with diagnosed OC could not be correlated with any clinical data and preoperative serum p53 AAb status had no evident value.
AB - The p53 gene, a tumour suppressor gene located on the short arm of chromosome 17 (17p13), is frequently mutated in various human tumours. Accumulation of p53 protein in neoplastic cells and its release following tumour necrosis can lead to development of circulating autoantibodies (AAb) against p53. Earlier studies of ovarian cancer (OC) patients reported different frequencies of p53 AAb and conclusions regarding the clinical and prognostic value of these AAb have not been in agreement. We therefore analysed for the presence of p53 AAb in a total of 227 preoperative serum samples from 193 OC patients and 34 patients with ovarian borderline tumours, and, in addition, serum samples from 86 healthy controls. An enzyme-linked immunosorbent assay (ELISA) was used to measure serum IgG antibodies against p53. The p53 protein used in the assay was produced as a hexahistidine-tagged fusion protein by baculovirus-infected Spodoptera frugiperda cells. Cut-off values for p53 AAb were evaluated, and correlations of p53 AAb with clinical-, biochemical data and survival were examined. We found a low sensitivity for p53 AAb alone, and no major additional effect of the detection rate of CA125 was found. No significant associations were found between p53 AAb and clinical stage, age, histological subtype and radicality after primary surgery. In contrast, we found significantly elevated CA125 levels in p53 AAb-positive patients compared to lower CA125 levels in p53 AAb-negative patients (p=0.003). No significant differences were found between p53 AAb-positive and p53 AAb-negative patients in the univariate and multivariate survival analyses. In conclusion, in a screening study for OC serum p53 AAb levels are of no diagnostic value, even if combined with the tumour marker CA125. The presence of increased serum p53 AAb in patients with diagnosed OC could not be correlated with any clinical data and preoperative serum p53 AAb status had no evident value.
KW - Adenocarcinoma, Papillary/blood
KW - Adult
KW - Aged
KW - Autoantibodies/blood
KW - CA-125 Antigen/blood
KW - Denmark
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Humans
KW - Middle Aged
KW - Multivariate Analysis
KW - Ovarian Neoplasms/blood
KW - Predictive Value of Tests
KW - Proportional Hazards Models
KW - ROC Curve
KW - Recombinant Proteins/immunology
KW - Tumor Suppressor Protein p53/immunology
UR - https://www.scopus.com/pages/publications/0036694888
U2 - 10.1034/j.1600-0463.2002.11007805.x
DO - 10.1034/j.1600-0463.2002.11007805.x
M3 - Journal article
C2 - 12390412
SN - 0903-4641
VL - 110
SP - 545
EP - 553
JO - APMIS - Journal of Pathology, Microbiology and Immunology
JF - APMIS - Journal of Pathology, Microbiology and Immunology
IS - 7-8
ER -